Verve Therapeutics/$VERV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verve Therapeutics
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Ticker
$VERV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
274
ISIN
US92539P1012
Website
VERV Metrics
BasicAdvanced
$1B
-
-$2.10
1.83
-
Price and volume
Market cap
$1B
Beta
1.83
52-week high
$11.41
52-week low
$2.86
Average daily volume
6.3M
Financial strength
Current ratio
9.843
Quick ratio
9.59
Long term debt to equity
12.274
Total debt to equity
14.495
Profitability
EBITDA (TTM)
-201.615
Gross margin (TTM)
-252.99%
Net profit margin (TTM)
-303.64%
Operating margin (TTM)
-349.68%
Effective tax rate (TTM)
-0.18%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-19.35%
Return on equity (TTM)
-34.26%
Valuation
Price to revenue (TTM)
16.328
Price to book
2.12
Price to tangible book (TTM)
2.12
Price to free cash flow (TTM)
-6.622
Free cash flow yield (TTM)
-15.10%
Free cash flow per share (TTM)
-170.64%
Growth
Revenue change (TTM)
271.44%
Earnings per share change (TTM)
-25.79%
3-year earnings per share growth (CAGR)
-16.26%
What the Analysts think about VERV
Analyst ratings (Buy, Hold, Sell) for Verve Therapeutics stock.
Bulls say / Bears say
Verve Therapeutics' VERVE-102 treatment demonstrated promising results in the Heart-2 Phase 1b clinical trial, leading to multiple analysts raising their price targets and ratings for the company. (finviz.com)
Institutional investors have shown increased confidence in Verve Therapeutics, with BVF Inc. IL boosting its stake by 962.2% in the fourth quarter, now owning approximately 8.16% of the company. (marketbeat.com)
Verve Therapeutics' participation in the 43rd Annual J.P. Morgan Healthcare Conference highlights its active engagement with the investment community and potential for future collaborations. (stocknews.com)
Verve Therapeutics faced a significant share price decline after releasing early-stage clinical trial data for VERVE-101, with concerns about its differentiation from existing treatments and reports of elevated liver enzymes in some patients. (investing.com)
A shareholder lawsuit alleges that Verve Therapeutics misled investors about a clinical trial for its cholesterol medicine, raising concerns about transparency and potential legal challenges. (bloomberglaw.com)
Renaissance Technologies LLC reduced its position in Verve Therapeutics by 36.8% in the fourth quarter, indicating a potential lack of confidence from a notable institutional investor. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
VERV Financial Performance
Revenues and expenses
VERV Earnings Performance
Company profitability
VERV News
AllArticlesVideos
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
GlobeNewsWire·1 week ago
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
Business Wire·2 weeks ago
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verve Therapeutics stock?
Verve Therapeutics (VERV) has a market cap of $1B as of June 30, 2025.
What is the P/E ratio for Verve Therapeutics stock?
The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of June 30, 2025.
Does Verve Therapeutics stock pay dividends?
No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Verve Therapeutics dividend payment date?
Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Verve Therapeutics?
Verve Therapeutics (VERV) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.